Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

No previous study has investigated prospectively the quantitative effect of treatment on antiendometrial antibody levels in endometriosis. We measured antiendometrial antibody levels by an enzyme-linked immunosorbent assay in 35 women with laparoscopically proved endometriosis who were treated for 6 months with danazol (N = 11) or nafarelin (N = 24) in a randomized double-blind study. Levels before treatment were significantly higher than in a control group (P less than .001). Levels were lowered by treatment, but to a significant extent only in the nafarelin group (P less than .001) (danazol group: P = .091). Our data suggest that in relation to antiendometrial antibodies, nafarelin has a suppressive effect which has previously been ascribed only to danazol.


Journal article


Obstet Gynecol

Publication Date





914 - 918


Adult, Autoantibodies, Danazol, Double-Blind Method, Endometriosis, Endometrium, Enzyme-Linked Immunosorbent Assay, Female, Gonadotropin-Releasing Hormone, Humans, Multicenter Studies as Topic, Nafarelin, Pelvic Neoplasms, Pregnadienes, Prospective Studies, Randomized Controlled Trials as Topic